

Wconc

said mutagenesis is other than only by means of a transposon inserted into the gene, wherein said *Shigella* does not comprise an active copy of said *icsA*.

86. (New) The *Shigella* of claim 85, wherein a marker gene is inserted into said mutagenized *icsA* gene.

87. (New) A vaccine comprising the *Shigella* of claim 85 and a pharmaceutically acceptable vehicle.

REMARKS

Entry of this Supplemental Amendment and timely reconsideration of this application is respectfully requested.

With entry of this Amendment, claims 24-30, 32-41, and 43-87 are pending in this application. Claim 38 is withdrawn from consideration as drawn to a nonelected invention.


Support for the newly added claims is found throughout the specification and, for example, at Page 21, lines 28-35. Accordingly, applicants submit that no new matter is added by this amendment and respectfully request that the amendment be entered.

Applicants respectfully request the reconsideration and reexamination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Kenneth J. Meyers
Reg. No. 25,146

Dated: November 9, 2001

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000